Dear Editor, We thank Bowers et al. 1 for their considered comments of the VISION pilot trial results. based on the available evidence at that time, the choice of outcome measures was appropriate, as we explain below.
VISION trial planning preceded the publication of a Cochrane systematic review on interventions for visual field loss following stroke. 2 Thus, a literature review by the trial team in 2009 reviewed the outcome measures reported by others [eg, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] ]. From this review, for all studies reporting outcomes for visual scanning training, visual field assessment was the only outcome measure (as a primary or secondary outcome measure) consistently used across all studies. For studies reporting outcomes for prism wear, all but one study 10 reported visual field assessment (with/without prism to consider field expansion effect).
As visual field assessment was consistently measured in all the key previous studies, it was an important outcome measure to consider in the VISION trial. Previous studies of interventions for hemianopia, particularly visual scanning training, had reported some apparent recovery in visual field defects (measured by visual field assessment) despite no change in objective measurements of visual field defect boundary. This was reported as being due to compensatory processes including better stimuli detection and faster reaction times to stimuli in the hemianopic field, along with unstable central fixation with eye movements towards the hemianopic side. [14] [15] [16] [17] However, there was insufficient information on the extent of variations that might occur in visual field measurements with natural adaptation (captured through the control arm) versus adaptation following different interventions (visual scanning training or prism therapy); we wished to explore this further.
Participants in the VISION trial could be recruited from 2 weeks to 6 months post-stroke onset. Bowers et al. correctly note that "prior research suggests there may be spontaneous recovery of the visual field up to 3-6 months following stroke". 18, 19 Because of this, many studies recruit participants after at least 6 months post-stroke onset to ensure stability of hemianopia. However, it is also known that about half of stroke survivors with hemianopia show no recovery of visual field loss 18, 19 and notably there are a number of reported studies that recruited participants with hemianopia at earlier time periods. An important outcome measure to include in any intervention trial is adverse event rate. The VISION trial sought to ensure that these were reported specific to the time period when interventions were used (ie, whilst wearing prism glasses or completing visual search training) highlighting a considerable difference between groups of 69% reported adverse events for the prism group and 7% for the visual search training group (0% for standard care). When planning the use of participant diaries, a key consideration was to ensure that participants could report their perceptions of intervention freely without clinician influence. We took specific care to ensure that participant diaries were completed at home and were reviewed only by independent blinded assessors.
A final aspect we should like to highlight is adherence to the CONSORT guidance when reporting trials. We followed the correct procedures of publishing our trial protocol 27 and ensured that the trial was conducted according to the predetermined design. When publishing the final results of the trial, we adhered to CONSORT reporting guidelines and reported all the outcome measures stipulated in the protocol.
In conclusion, it is positive to see the emerging research for treat- 
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